functional ingredients for glp-1 How is reshaping ingredient strategy What do the new 'GLP-1

In October 2023, A Research Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW) trial assessing the effect of semaglutide versus placebo on the progression of renal impairment in people with T2DM and chronic kidney disease was stopped prematurely due to results of an interim analysis showing significant efficacy of semaglutide with full results due to be released in the first half of 2024 [39]

HDRx Functional Medicine

For autoimmune conditions, where those goals may not apply, lower doses may theoretically make sense

For the lab-based study, human retinal endothelial cells were treated with a range of different concentrations of semaglutide